Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2161 to 2175 of 9035 results

  1. Olomorasib with pembrolizumab for untreated KRAS G12C mutation- and PD-L1-positive unresectable advanced non-small-cell lung cancer [GID-TA12003]

    Awaiting development Reference number: GID-TA12003 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Olomorasib in combination for untreated KRAS G12C mutation-positive unresectable advanced non-squamous non-small-cell lung cancer [GID-TA12001]

    Awaiting development Reference number: GID-TA12001 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Headaches (update): Prophylactic treatment of migraine - Candesartan

    In development Reference number: GID-NG10472 Expected publication date: TBC

    NICE guideline
    In development

  4. Olezarsen for treating severe hypertriglyceridaemia [GID-TA12016]

    Awaiting development Reference number: GID-TA12016 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Amlitelimab for treating moderate to severe atopic dermatitis in people 12 years and over [GID-TA12005]

    Awaiting development Reference number: GID-TA12005 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Grazax for treating allergic rhinitis and conjunctivitis caused by grass pollen in people 5 years and over [GID-TA12010]

    Awaiting development Reference number: GID-TA12010 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Obsessive-compulsive disorder and body dysmorphic disorder

    In development Reference number: GID-QS10200 Expected publication date:  16 February 2027

    Quality standard
    In development

  8. Emactuzumab for treating localised or diffuse tenosynovial giant cell tumours when surgery is unsuitable [GID-TA12000]

    Awaiting development Reference number: GID-TA12000 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Povorcitinib for treating non-segmental vitiligo [GID-TA12019]

    Awaiting development Reference number: GID-TA12019 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Povorcitinib for treating prurigo nodularis [GID-TA12018]

    Awaiting development Reference number: GID-TA12018 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Encaleret for treating autosomal dominant hypocalcaemia type 1 in people 16 years and over [GID-TA12008]

    Awaiting development Reference number: GID-TA12008 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Nirogacestat for treating desmoid tumours [ID6453]

    In development Reference number: GID-TA11559 Expected publication date:  05 August 2026

    Technology appraisal guidance
    In development

  13. Nirogacestat for treating desmoid tumours [ID6453]: draft guidance

    We are listening to your views on this Technology appraisal guidance. Comments close 1 June 2026.

    Technology appraisal guidance
    In consultation

  14. Lonapegsomatropin for treating growth hormone deficiency in people 3 to 17 years [GID-TA12013]

    Awaiting development Reference number: GID-TA12013 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Lemborexan for treating insomnia [GID-TA12011]

    Awaiting development Reference number: GID-TA12011 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development